通过抑制ERα-Tau结合,雌激素减轻了sevoflurane诱导的神经毒性
Feixiang Li1,2, Bingqing Gong1, Zichen Song1
1Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin Institute of Anesthesiology, Tianjin, 300052, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|September 6, 2025
概括
在雌性小鼠中,雌激素通过调节雌激素受体α-Tau相互作用来保护sevoflurane的神经毒性. 这一发现对于了解麻醉风险和制定有针对性的干预措施至关重要.
科学领域:
- 神经科学
- 麻醉学
- 内分泌学
背景情况:
- 西沃弗拉的神经毒性取决于年龄,性别差异和雌激素的作用尚不清楚.
- 现有研究强调的保护作用, 但雌激素对麻醉引起的神经毒性的影响需要调查.
研究的目的:
- 对不同年龄组小鼠的神经毒性的性别特异性影响进行研究.
- 阐明雌激素及其受体α (ERα) 在减轻sevoflurane诱导的神经毒性的作用.
主要方法:
- 评估神经毒性标志物,包括背部海马CA1区域的tau酸化,认知功能和神经元结构完整性.
- 使用雌激素受体对抗剂,抑制剂,过度表达的病毒载体,ERα淘汰模型,GRAMM对接,ITC和竞争ELISA来探索机制.
主要成果:
- 在中年雌性小鼠中,sevoflurane诱导了神经毒性,而不是雄性小鼠. 雌激素的使用改善了这些女性的tau酸化,认知缺陷和神经元信号/结构变化.
- 雌激素的保护作用依赖于ERα,这在ERα淘汰小鼠中被证明是无效的.
- 在老年女性中,雌激素的保护作用取决于ERα的上调,发现雌激素和Tau有竞争性地与ERα结合,这种相互作用由sevoflurane增强.
结论:
- 以性别和年龄为依据,雌激素对抗sevoflurane诱导的神经毒性具有保护作用.
- 这些发现表明,雌激素主要通过调节ERα-Tau相互作用来减轻sevoflurane的神经毒性,从而成为潜在的治疗标.
更多相关视频
04:56In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
6.7K
03:02Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
Published on: July 25, 2025
106
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:26Anxiolytic Drugs: Overview
479
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
479
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
632
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
632
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
236
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
236